Showing 1 to 1 of 1 results
forbes.com
🌐 85% Global Worthiness


IRA's Impact: Lower Drug Costs for Medicare Cancer Patients
The Inflation Reduction Act capped annual out-of-pocket costs for Medicare Part D prescription drugs at $3,300 in 2024 and $2,000 in 2025, resulting in a 50% year-over-year increase in oncology prescription volumes between 2023 and 2024, significantly benefiting cancer patients.
IRA's Impact: Lower Drug Costs for Medicare Cancer Patients
The Inflation Reduction Act capped annual out-of-pocket costs for Medicare Part D prescription drugs at $3,300 in 2024 and $2,000 in 2025, resulting in a 50% year-over-year increase in oncology prescription volumes between 2023 and 2024, significantly benefiting cancer patients.
Progress
40% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results